Previous close | 45.85 |
Open | 45.85 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 70.00 |
Expiry date | 2025-01-17 |
Day's range | 45.85 - 45.85 |
Contract range | N/A |
Volume | |
Open interest | 136 |
(Bloomberg) -- Two scientists won the Nobel Prize in medicine for research that laid the groundwork for some of the best-selling medicines of all time: the messenger-RNA vaccines against Covid-19.Most Read from BloombergWhy a US Recession Is Still Likely — and Coming SoonSevere Crash Is Coming for US Office Properties, Investors SayOnce Unthinkable Bond Yields Now the New Normal for MarketsCongress Averts US Government Shutdown Hours Before DeadlineAirbnb Is Fundamentally Broken, Its CEO Says. H
These companies are helping change medicine; they could make boatloads of money along the way.
Moderna (NASDAQ: MRNA) used to be a stock market star, climbing 1,700% from the start of 2020 through July of 2021. Investors liked that, and it clearly showed in the stock performance. After all, the vaccine is Moderna's only product right now, and demand for it has declined.